Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) CoSHSE:603127 -1.12%70 5-Year Yield-on-Cost % is 0.15 as of Sep. 15, 2026, which is 21% below its 10-year median of 0.19. GuruFocus rates SHSE:603127 with a GF Score™ of 70/100 and a GF Value™ of ¥16.96 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 60 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks worse than 98.33% on this metric.
The historical rank and industry rank for Joinn Laboratories (China) Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:603127'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.04 Med: 0.19 Max: 1.68
Current: 0.15
During the past 13 years, Joinn Laboratories (China) Co's highest Yield on Cost was 1.68. The lowest was 0.04. And the median was 0.19.
SHSE:603127's 5-Year Yield-on-Cost % is ranked worse than 98.33% of 60
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.665
vs SHSE:603127: 0.15
Joinn Laboratories (China) Co (SHSE:603127) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Joinn Laboratories (China) Co 5-Year Yield-on-Cost % Related Terms
SHSE:603127 vs TMO, DHR, NTRA: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's 5-Year Yield-on-Cost % falls into.
Joinn Laboratories (China) Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Joinn Laboratories (China) Co (SHSE:603127) has a 5-Year Yield-on-Cost % of 0.15 as of Sep. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Joinn Laboratories (China) Co and its competitors. This is 21% below median its historical median of 0.19. Over the past decade, Joinn Laboratories (China) Co's 5-Year Yield-on-Cost % has ranged from 0.04 to 1.68. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #59 out of 60 companies in the Medical Diagnostics & Research industry, placing it in the top 98.3%.
Is Joinn Laboratories (China) Co's 5-Year Yield-on-Cost % too high?
Joinn Laboratories (China) Co's current 5-Year Yield-on-Cost % of 0.15 is 21% below median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 1.68. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.67. Joinn Laboratories (China) Co's value of 0.15 is 94.4% below this industry median. Based on the distribution chart, Joinn Laboratories (China) Co ranks #59 out of 60 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Joinn Laboratories (China) Co has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #59 out of 60 companies for 5-Year Yield-on-Cost %. This places Joinn Laboratories (China) Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.67. Joinn Laboratories (China) Co's value of 0.15 is 94.4% below this benchmark. Historically, Joinn Laboratories (China) Co's own 5-Year Yield-on-Cost % has ranged from 0.04 to 1.68 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 2.67, Joinn Laboratories (China) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.67, based on 60 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joinn Laboratories (China) Co's current 5-Year Yield-on-Cost % of 0.15 is 94.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Joinn Laboratories (China) Co and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joinn Laboratories (China) Co's current 5-Year Yield-on-Cost % is 0.15, which is 21% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥16.96, compared to a current price of ¥42.32 — trading 149.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.15, which is 21% below median its 10-year median of 0.19 and 94.4% below the Medical Diagnostics & Research industry median of 2.67. Joinn Laboratories (China) Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current 5-Year Yield-on-Cost % is 0.15 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥42.32 is trading 149.5% above its estimated GF Value™ of ¥16.96.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
5-Year Yield-on-Cost %: 0.15 (21% below median its 10-year median of 0.19)
GF Value™: ¥16.96 vs. price of ¥42.32 (149.5% above fair value)
Industry Position: 94.4% below the Medical Diagnostics & Research median (#59 of 60)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
70GF Score
Get the complete analysis for SHSE:603127
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
